DeepMed Research

FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

African Cancer Genome: GMD

Recruiting

Conditions: Prostate Cancer
Breast Cancer

Interventions: Other: Standard of Care

First Posted Date: 2023-03-06

Last Posted Date: 2025-03-13

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1500

Registration Number: NCT05754658

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Couples' QOL in Metastatic Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Behavioral: Adapted Intimacy Enhancement
Behavioral: Intimacy Facts and Resources

First Posted Date: 2022-12-05

Last Posted Date: 2025-01-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 110

Registration Number: NCT05636943

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Early Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Melanoma

Interventions: Drug: CBL0137
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2022-08-12

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT05498792

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

Phase 3

Suspended

Conditions: Surgery
Cancer

Interventions: Procedure: Intensified post-discharge surveillance
Procedure: Standard post-discharge surveillance

First Posted Date: 2022-07-12

Last Posted Date: 2024-12-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 880

Registration Number: NCT05454280

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Phase 2

Recruiting

Conditions: Small-cell Lung Cancer
Neuroendocrine Carcinoma

Interventions: Drug: Iadademstat
Drug: Paclitaxel

First Posted Date: 2022-06-15

Last Posted Date: 2024-08-23

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 42

Registration Number: NCT05420636

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

First Posted Date: 2022-06-01

Last Posted Date: 2023-07-17

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT05400577

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

PHL Treatment in Pancreatic Cancer

Early Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Other: Neoadjuvant therapy and surgery only (Control)
Combination Product: Paricalcitol, Hydroxychloroquine, Losartan

First Posted Date: 2022-05-09

Last Posted Date: 2025-04-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 20

Registration Number: NCT05365893

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: FOLFIRINOX

First Posted Date: 2022-05-04

Last Posted Date: 2025-04-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 37

Registration Number: NCT05360732

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Women's Health Communication Study

Not Applicable

Completed

Conditions: Gynecologic Cancer

Interventions: Behavioral: Sexual and Menopausal Health Resources Only
Behavioral: Starting the Conversation

First Posted Date: 2022-05-04

Last Posted Date: 2023-02-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 32

Registration Number: NCT05359952

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1

Recruiting

Conditions: HER2 Gene Mutation
Gastric Cancer
Gastrointestinal Cancer

Interventions: Drug: Neratinib Pill
Drug: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

First Posted Date: 2022-03-10

Last Posted Date: 2025-02-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 18

Registration Number: NCT05274048

Locations: 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy